197 related articles for article (PubMed ID: 22816430)
1. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.
Kaneko MK; Kunita A; Abe S; Tsujimoto Y; Fukayama M; Goto K; Sawa Y; Nishioka Y; Kato Y
Cancer Sci; 2012 Nov; 103(11):1913-9. PubMed ID: 22816430
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
[TBL] [Abstract][Full Text] [Related]
3. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK
Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352
[TBL] [Abstract][Full Text] [Related]
4. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
Kaneko MK; Ohishi T; Nakamura T; Inoue H; Takei J; Sano M; Asano T; Sayama Y; Hosono H; Suzuki H; Kawada M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):167-174. PubMed ID: 33085938
[TBL] [Abstract][Full Text] [Related]
5. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.
Abe S; Morita Y; Kaneko MK; Hanibuchi M; Tsujimoto Y; Goto H; Kakiuchi S; Aono Y; Huang J; Sato S; Kishuku M; Taniguchi Y; Azuma M; Kawazoe K; Sekido Y; Yano S; Akiyama S; Sone S; Minakuchi K; Kato Y; Nishioka Y
J Immunol; 2013 Jun; 190(12):6239-49. PubMed ID: 23690472
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
[TBL] [Abstract][Full Text] [Related]
7. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies.
Nakazawa Y; Takagi S; Sato S; Oh-hara T; Koike S; Takami M; Arai H; Fujita N
Cancer Sci; 2011 Nov; 102(11):2051-7. PubMed ID: 21824222
[TBL] [Abstract][Full Text] [Related]
8. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
9. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
[TBL] [Abstract][Full Text] [Related]
11. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N
Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501
[TBL] [Abstract][Full Text] [Related]
12. Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog Podoplanin.
Kato Y; Mizuno T; Yamada S; Nakamura T; Itai S; Yanaka M; Sano M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2018 Nov; 37(5):218-223. PubMed ID: 30362926
[TBL] [Abstract][Full Text] [Related]
13. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2.
Ogasawara S; Kaneko MK; Price JE; Kato Y
Hybridoma (Larchmt); 2008 Aug; 27(4):259-67. PubMed ID: 18707544
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain.
Kato Y; Kaneko MK; Kuno A; Uchiyama N; Amano K; Chiba Y; Hasegawa Y; Hirabayashi J; Narimatsu H; Mishima K; Osawa M
Biochem Biophys Res Commun; 2006 Nov; 349(4):1301-7. PubMed ID: 16979138
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Monoclonal Antibody LpMab-7 Recognizing Non-PLAG Domain of Podoplanin.
Oki H; Kaneko MK; Ogasawara S; Tsujimoto Y; Liu X; Sugawara M; Takakubo Y; Takagi M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):174-80. PubMed ID: 26090595
[TBL] [Abstract][Full Text] [Related]
16. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
Kato Y; Kaneko MK
Sci Rep; 2014 Aug; 4():5924. PubMed ID: 25080943
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy evaluation of radioimmunotherapy with
Sudo H; Tsuji AB; Sugyo A; Saga T; Kaneko MK; Kato Y; Higashi T
Cancer Sci; 2019 May; 110(5):1653-1664. PubMed ID: 30801908
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.
Kato Y; Vaidyanathan G; Kaneko MK; Mishima K; Srivastava N; Chandramohan V; Pegram C; Keir ST; Kuan CT; Bigner DD; Zalutsky MR
Nucl Med Biol; 2010 Oct; 37(7):785-94. PubMed ID: 20870153
[TBL] [Abstract][Full Text] [Related]
19. Platelet-activating factor podoplanin: from discovery to drug development.
Takemoto A; Miyata K; Fujita N
Cancer Metastasis Rev; 2017 Jun; 36(2):225-234. PubMed ID: 28674748
[TBL] [Abstract][Full Text] [Related]
20. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.
Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N
Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
